Studying the Interplay Between Apolipoprotein E and Education on Cognitive Decline in Centenarians Using Bayesian
Qingyan Xiang1, Stacy Lynn Andersen2, Thomas T Perls2
1Department of Biostatistics, Boston University School of Public Health, Boston, MA, United States.
Frontiers in Genetics
|January 25, 2021
Summary
Education may modify the impact of Apolipoprotein E (APOE) gene variants on cognitive function in centenarians. Higher education may lessen APOE e2
Area of Science:
- Neuroscience
- Genetics
- Gerontology
Background:
- Apolipoprotein E (APOE) gene variants influence cognitive decline and Alzheimer's disease risk.
- The APOE e4 allele is linked to increased risk, while e2 may offer protection.
- The interaction between APOE and education on cognition, especially in extreme old age, is not well understood.
Purpose of the Study:
- To investigate the interplay between APOE alleles and education on cognitive function in centenarians.
- To apply advanced statistical methods suitable for bounded and skewed neuropsychological data.
Main Methods:
- Bayesian beta regression analysis was employed.
- Longitudinal cognitive function data from a cohort of centenarians was analyzed.
- The effects of APOE alleles (e2, e3, e4) and education level were assessed.
Main Results:
- Confirmed negative association between age and cognition, and a beneficial effect of education, even in centenarians with the APOE e3 allele.
- Demonstrated a significant interaction between APOE genotype and education level on cognitive performance.
- Observed an antagonistic interaction: higher education potentially reduced the protective effect of APOE e2 and amplified the detrimental effect of APOE e4.
Conclusions:
- Education level significantly modifies the association between APOE genotype and cognitive function in extreme old age.
- Educational attainment may influence the neuroprotective or detrimental effects of specific APOE alleles.
- Findings highlight the complex interplay of genetic and environmental factors in maintaining cognitive health in centenarians.
Keywords:
apolipoprotein Ebeta regressionblessed information-memory-concentration testcentenarianscognitive functionMore Related Videos
12:28Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
17.9K
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
8.0K
Related Concept Videos
01:30Cognitive Development During Adulthood
517
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
517
01:26Alzheimer's Disease: Overview
1.1K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.1K
01:22Alzheimer's Disease: Treatment
586
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
586
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
95
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
95
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
85
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
85
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
99
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
99